<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="48648">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01980628</url>
  </required_header>
  <id_info>
    <org_study_id>PCYC-1121-CA</org_study_id>
    <nct_id>NCT01980628</nct_id>
  </id_info>
  <brief_title>Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed/Refractory Marginal Zone Lymphoma</brief_title>
  <official_title>A Multicenter, Open-Label, Phase 2 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Subjects With Relapsed/Refractory Marginal Zone Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pharmacyclics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Pharmacyclics</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United States: Institutional Review Board</authority>
    <authority>Belgium: Federal Agency for Medicines and Health Products, FAMHP</authority>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <authority>France: National Agency for the Safety of Medicine and Health Products</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 2, open-label, non-randomized, monotherapy study to evaluate the safety and efficacy
      of ibrutinib in subject with relapsed/refractory Marginal Zone Lymphoma (MZL).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ibrutinib is a first-in-class, potent, orally administered covalent inhibitor of Bruton's
      tyrosine kinase (BTK).  Inhibition of BTK blocks downstream B-cell receptor (BCR) signaling
      pathways and thus prevents B-cell proliferation. In vitro, ibrutinib inhibits purified BTK
      and selected members of the kinase family with 10-fold specificity compared with non-BTK
      kinases.  Phase 1 and 2 studies of ibrutinib in B-cell malignancies demonstrate modest
      toxicity and significant single agent activity in a variety of B-cell malignancies,
      including NHL.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>To evaluate efficacy using the Overall Response Rate (ORR) as assessed by an Independent Review Committee (IRC) in subjects with MZL</measure>
    <time_frame>36 weeks after last patient enrolled</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate efficacy parameter such as duration of response (DOR) to ibrutinib in subjects with MZL</measure>
    <time_frame>36 weeks after last patient enrolled</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency, severity, and relatedness of adverse events</measure>
    <time_frame>36 weeks after last patient enrolled</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the plasma pharmacokinetics of ibrutinib and the metabolite, PCI-45227</measure>
    <time_frame>36 weeks after last patient enrolled</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate efficacy parameter such as progression-free survival (PFS) to ibrutinib in subjects with MZL</measure>
    <time_frame>36 weeks after last patient enrolled</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate efficacy parameter such as overall survival (OS) to ibrutinib in subjects with MZL</measure>
    <time_frame>36 weeks after last patient enrolled</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>To evaluate prognostic and predictive biomarkers relative to treatment outcomes</measure>
    <time_frame>36 weeks after last patient enrolled</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Marginal Zone Lymphoma</condition>
  <condition>B-cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>ibrutinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ibrutinib capsules: 560 mg once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ibrutinib</intervention_name>
    <arm_group_label>ibrutinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion criteria:

          -  Histologically documented marginal zone lymphoma (including splenic, nodal, and
             extranodal sub-types)

          -  Previously received one or more lines of therapy including at least one CD20-directed
             regimen (either as monotherapy or as chemoimmunotherapy) with documented failure to
             achieve at least PR or documented PD after, the most recent systemic treatment
             regimen

          -  Men and women ≥18 years of age

          -  ECOG performance status of ≤2

          -  ≥1 measurable disease site on CT scan (&gt;1.5 cm in longest dimension). Lesions in
             anatomical locations (such as extremities or soft tissue lesions) that are not well
             visualized by CT may be measured by MRI instead.

          -  Life expectancy of &gt;3 months, in the opinion of the investigator

        Key Exclusion criteria:

          -  Medically apparent CNS lymphoma or leptomeningeal disease

          -  History of other malignancies except adequately treated non melanoma skin cancer,
             curatively treated in-situ cancer, or other solid tumors curatively treated with no
             evidence of disease for ≥2 years

          -  History of allogeneic stem-cell (or other organ) transplantation

          -  Any chemotherapy, anticancer antibodies, or other systemic anticancer therapy within
             21 days of the first dose of study drug

          -  Any external beam radiation therapy within 6 weeks prior to the first dose of the
             study drug

          -  Concurrent use of warfarin or other vitamin K antagonists

          -  Concurrent use of a strong CYP3A inhibitor.  Subjects who have received a strong
             CYP3A inhibitor prior to entering the study must have discontinued therapy for at
             least 5 half lives of the prohibited medication.

          -  Recent infection requiring IV anti-infective treatment that was completed ≤14 days
             before the first dose of study drug

          -  Unresolved toxicities from prior anti-cancer therapy, defined as having not resolved
             to CTCAE Grade 0 or 1, or to the levels dictated in the eligibility criteria with the
             exception of alopecia

          -  Inadequate organ function as defined on laboratory tests
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Darrin Beaupre, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Pharmacyclics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Susie Tanamly</last_name>
    <phone>855-427-8846</phone>
    <email>medinfo@pcyc.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Deepali Suri</last_name>
    <phone>855-427-8846</phone>
    <email>medinfo@pcyc.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cheryl Corpus</last_name>
      <phone>626-256-4673</phone>
      <phone_ext>31311</phone_ext>
      <email>ccorpus@coh.org</email>
    </contact>
    <investigator>
      <last_name>Robert Chen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Baudelio Gutierrez</last_name>
      <phone>310-582-4046</phone>
      <email>bgutierrez@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Sven deVos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California San Diego Moores Cancer Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jenny Perales</last_name>
      <phone>858-822-6937</phone>
      <email>j7perez@ucsd.edu</email>
    </contact>
    <investigator>
      <last_name>Januario Castro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Bar-Nur</last_name>
      <phone>561-472-1696</phone>
      <email>jbar-nur@flcancer.com</email>
    </contact>
    <investigator>
      <last_name>Robert Jacobson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Zavala</last_name>
      <email>jose.zavala@northwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Shuo Ma, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathern Thomason</last_name>
      <phone>313-916-7827</phone>
      <email>kthomas9@hfhs.org</email>
    </contact>
    <investigator>
      <last_name>Nalini Janakiraman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lymphoma Service</last_name>
      <phone>646-497-9137</phone>
    </contact>
    <investigator>
      <last_name>Ariela Noy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Research Alliance</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Colleen Kats</last_name>
      <phone>855-737-2873</phone>
      <phone_ext>121</phone_ext>
      <email>ckats@researchcra.com</email>
    </contact>
    <investigator>
      <last_name>Morton Coleman, MD, FACP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Martin, MD</last_name>
      <phone>646-962-2068</phone>
      <email>pem9019@med.cornell.edu</email>
    </contact>
    <investigator>
      <last_name>Peter Martin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Penn State Milton S. Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Capper</last_name>
      <phone>717-531-0003</phone>
      <phone_ext>285453</phone_ext>
      <email>ccapper@hmc.psu.edu</email>
    </contact>
    <investigator>
      <last_name>Christopher Ehmann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lacey Hedin</last_name>
      <phone>206-667-2731</phone>
      <email>lhedin@fhcrc.org</email>
    </contact>
    <investigator>
      <last_name>Stephen Smith, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Gent</name>
      <address>
        <city>Ghent</city>
        <state>Oost-Vlaanderen</state>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Fritz Offner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Henri-Becquerel</name>
      <address>
        <city>Rouen Cedex 1</city>
        <state>Haute-Normandie</state>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laure Gaillon</last_name>
      <phone>+33232082220</phone>
      <email>laure.ditullio-gaillon@chb.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Herve Tilly</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <state>Ile de France</state>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Feriel Bouabbas</last_name>
      <phone>+33149814182</phone>
      <email>feriel.bouabbas@hmn.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Corinne Haioun</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Louis</name>
      <address>
        <city>Paris Cedex 10</city>
        <state>Ile de France</state>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Catherine Thieblemont</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU de Limoges - Hôpital Dupuytren</name>
      <address>
        <city>Limoges Cedex</city>
        <state>Limousin, Lorraine</state>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dominique Bordessoule</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Régional Universitaire de Lille - Hôpital Claude Huriez</name>
      <address>
        <city>Lille Cedex</city>
        <state>Nord pas de Calais</state>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carole Delecroix</last_name>
      <phone>+33320444284</phone>
      <email>carole.delecroix@chru-lille.fr</email>
    </contact>
    <investigator>
      <last_name>Franck Morschhauser</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHD Vendée, Site de La Roche-sur-Yon, Les Oudairies</name>
      <address>
        <city>La Roche-sur-Yon Cedex 9</city>
        <state>Pays de la Loire</state>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hélène Renoul</last_name>
      <phone>+33251446467</phone>
      <email>helene.renoul@chd-vendee.fr</email>
    </contact>
    <investigator>
      <last_name>Hervé Maisonneuve</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Nantes, Hotel Dieu</name>
      <address>
        <city>Nantes cedex 1</city>
        <state>Pays de la Loire</state>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexis Morice</last_name>
      <phone>+33240084030</phone>
      <email>alexis.morice@chu-nantes.fr</email>
    </contact>
    <investigator>
      <last_name>Steven LeGouill</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre Bénite Cedex</city>
        <state>Rhone- Alpes</state>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Severine Seemann</last_name>
      <phone>+33478864337</phone>
      <email>severine.seemann@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Gilles Salles</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Rennes, Hôpital Pontchaillou</name>
      <address>
        <city>Rennes cedex 9</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Bernard</last_name>
      <phone>+33299284321</phone>
      <email>anna.bernard@chu-rennes.fr</email>
    </contact>
    <investigator>
      <last_name>Sophie De Guibert, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Belgium</country>
    <country>France</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 28, 2014</lastchanged_date>
  <firstreceived_date>October 29, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MZL</keyword>
  <keyword>NHL</keyword>
  <keyword>SMZL</keyword>
  <keyword>NMZL</keyword>
  <keyword>MALT</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, B-Cell, Marginal Zone</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
